BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript Summary
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript Summary
Selling, General and Administrative expenses reduced to $825,000 in Q3 2024 from $1.1 million in Q3 2023.The following is a summary of the BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript:
以下是biocardia, Inc. (BCDA) 2024年第三季度业绩会会议记录的摘要：
Financial Performance:
财务表现：
BioCardia reported a decrease in total expenses by 41% from Q3 2023 to Q3 2024, with $1.8 million in Q3 2024 compared to $3.0 million in Q3 2023.
Research and Development expenses decreased to $931,000 in Q3 2024, down from $1.9 million in Q3 2023, attributed to the completion of enrollment in the CardiAMP Heart Failure I trial.
Selling, General and Administrative expenses reduced to $825,000 in Q3 2024 from $1.1 million in Q3 2023.
Net loss decreased to $1.7 million in Q3 2024 from $2.6 million in the third quarter of 2023.
Net cash used in operations totaled $2.6 million in Q3 2024, as compared to $2.4 million in Q3 2023.
biocardia在2024年第三季度的总支出相比于2023年第三季度减少了41%，在2024年第三季度的支出为180万，而2023年第三季度为300万。
研发支出在2024年第三季度减少至931,000美元，低于2023年第三季度的190万，主要归因于心脏再生治疗I期试验的入组完成。
销售、一般和行政支出从2023年第三季度的110万降至2024年第三季度的825,000。
净亏损从2023年第三季度的260万减少至2024年第三季度的170万。
2024年第三季度的运营净现金使用总额为260万，而2023年第三季度为240万。
Business Progress:
业务进展：
BioCardia is advancing two major clinical trials for CardiAMP cell therapy, looking toward cardiac repair without the need for surgery or immunosuppression.
Lead CardiAMP cell therapy for heart failure has received FDA breakthrough designation and is reimbursed by CMS.
Enrollment boost in CardiAMP Heart Failure II trial is expected due to protocol amendments and additional cell dosage adjustments.
The Morph DNA Steerable Introducer received FDA approval, enhancing cardiac procedures.
biocardia正在推进两项主要的心脏AMP电芯疗法临床试验，旨在实现无需手术或免疫抑制的心脏修复。
用于心衰的心脏AMP电芯疗法已获得FDA突破性设计，并得到康哲药业的报销。
由于协议修订和额外电芯剂量调整，预计心脏AMP心衰II试验的 enrollment 会增加。
Morph DNA可控引导器已获得FDA批准，提升了心脏程序的安全性。
Opportunities:
机会：
Expansion in the CardiAMP Heart Failure II trial with protocol amendment, allowing for increased eligibility and potential effectiveness.
Marketing the Morph DNA Steerable Introducer to other companies could provide substantial non-dilutive capital and expedite commercial expansion.
心脏AMP心衰II试验的扩展通过协议修订，允许更高的适应资格和潜在的有效性。
向其他公司销售Morph DNA可控引导器可以提供大量非稀释性资本，并加快商业扩展。
Risks:
风险：
Final data from the CardiAMP Heart Failure I trial pivotal for future product approvals might bear unexpected outcomes.
Delays in clinical trials due to natural disasters like hurricanes impacting timelines and operations.
来自CardiAMP心力衰竭I期试验的最终数据可能对未来产品审批产生意想不到的结果。
由于像飓风这样的自然灾害导致的临床试验延迟影响时间表和操作。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
